Status:
RECRUITING
Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany
Lead Sponsor:
Heidelberg University
Collaborating Sponsors:
German Research Foundation
University Düsseldorf
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Background: Borderline Personality Disorder (BPD) is a serious mental disorder. Mentalization-based treatment (MBT) is one evidence-based treatment for individuals with BPD. Specifically, MBT has been...
Eligibility Criteria
Inclusion
- Borderline Personality Disorder
- non-suicidal self injury or suicide attempts in the past two years as indicated by the IPDE item "repeated suicidal behaviours, gestures, threats or self-harm", one of which has occurred in the past six months
Exclusion
- acute substance use disorder (exception: cannabis dependency)
- diagnosis of schizophrenia or schizotypal personality disorder
- bipolar I disorder (DSM-5)
- cognitive impairment (IQ\<80) or evidence of organic brain disorder
- BMI\<16.5
- serious medical condition that will require hospitalization within the next year (e.g. cancer)
- no sufficient German language abilities
Key Trial Info
Start Date :
February 28 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
304 Patients enrolled
Trial Details
Trial ID
NCT06018272
Start Date
February 28 2024
End Date
March 31 2028
Last Update
May 10 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychologische Hochschule Berlin
Berlin, Germany
2
Clinic for Psychosomatic Medicine and Psychotherapy, University Hospital Düsseldorf
Düsseldorf, Germany
3
Heidelberg University
Heidelberg, Germany, 69115
4
Institute for Psychosocial Medicine, Psychotherapy and Psychooncology
Jena, Germany